Chai Discovery, a San Francisco-based startup, has introduced cutting-edge AI models for de novo antibody generation that demonstrate significantly improved success rates compared to existing protein models. The preprint reveals that these AI-driven techniques could accelerate antibody drug discovery pipelines, offering substantial potential to biotech firms focused on therapeutic antibodies.